Mass spectrometric profiling reveals association of N -glycan patterns with epithelial ovarian cancer progression
Tumor Biology · 2017-07 · 39 (7) · 101042831771624
DOI: 10.1177/1010428317716249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tumor Biology, online erschienen am 06.07.2017. Verfasst von Huanhuan Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: 1 Key Laboratory of Marine Drugs, Ministry of Education, Shandong Provincial Key Laboratory of Glycoscience and Glycoengineering, School of Medicine …. Hauptthemen laut MEDLINE: Glycomics. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Aberrant changes of N-glycan modifications on proteins have been linked to various diseases including different cancers, suggesting possible avenue for exploring their etiologies based on N-glycomic analysis. Changes in N-glycan patterns during epithelial ovarian cancer development have so far been investigated mainly using serum, plasma, ascites, and cell lines. However, changes in patterns of N-glycans in tumor tissues during epithelial ovarian cancer progression have remained largely undefined. To investigate whether changes in N-glycan patterns correlate with oncogenesis and progression of epithelial ovarian cancer, we profiled N-glycans from formalin-fixed paraffin-embedded tissue slides using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and quantitatively compared among different pathological grades of epithelial ovarian cancer and healthy controls. Our results show that among the 80 compositions of N-glycan detected, expression levels of high-mannose type were higher in epithelial ovarian cancer samples than that observed in healthy controls, accompanied by reduced levels of hybrid-type glycans. By applying receiver operating characteristic analysis, we show that a combined panel composed of four high-mannose and three fucosylated neutral complex N-glycans allows for good discrimination of epithelial ovarian cancer from healthy controls. Furthermore, using a statistical analysis of variance assay, we found that different N-glycan patterns, including 2 high-mannose-type, 2 fucosylated and sialylated complex structures, and 10 fucosylated neutral complex N-glycans, exhibited specific changes in N-glycan abundance across epithelial ovarian cancer grades. Together, our results provide strong evidence that N-glycomic changes are a strong indicator for epithelial ovarian cancer pathological grades and should provide avenues to identify novel biomarkers for epithelial ovarian cancer diagnosis and monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1 Key Laboratory of Marine Drugs, Ministry of Education, Shandong Provincial Key Laboratory of Glycoscience and Glycoengineering, School of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
- 2 Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
- 3 GuangDong Bio-Healtech Advanced Co., Ltd, Foshan, China.
- 4 Qingdao National Laboratory for Marine Science and Technology, Qingdao, China.
- 5 University of Chinese Academy of Sciences, Beijing, China.
Zitieren
APA
Chen, H., Deng, Z., Huang, C., Wu, H., Zhao, X., & Li, Y. (2017). Mass spectrometric profiling reveals association of N -glycan patterns with epithelial ovarian cancer progression. Tumor Biology, 39(7), 101042831771624. https://doi.org/10.1177/1010428317716249
Vancouver
Chen H, Deng Z, Huang C, Wu H, Zhao X, Li Y. Mass spectrometric profiling reveals association of N -glycan patterns with epithelial ovarian cancer progression. Tumor Biology. 2017;39(7):101042831771624. doi:10.1177/1010428317716249
BibTeX
@article{Chen2017,
author = {Chen, Huanhuan and Deng, Zaian and Huang, Chuncui and Wu, Hongmei and Zhao, Xia and Li, Yan},
title = {Mass spectrometric profiling reveals association of N -glycan patterns with epithelial ovarian cancer progression},
journal = {Tumor Biology},
year = {2017},
volume = {39},
number = {7},
pages = {101042831771624},
doi = {10.1177/1010428317716249}
}
EUVIMED